ARTHEx Biotech — Series A · €4.25M

Arthex is a preclinical biotech developing antisense RNA therapies for myotonic dystrophy type 1. Invivo Ventures and Advent France Biotechnology co-led this €4.25M round. It follows a €2.7M seed from Invivo and CDTI-Innvierte, bringing the total raised to €6.95M.

LeadInvivo Ventures, Advent France Biotechnology RoundSeries A Announced23 Jul 2020 CityValencia SectorHealthtech & Bio · Biotech Source I

Something wrong? Suggest a correction →